Optimer Pharmaceuticals to Webcast Investor and Analyst Reception on December 5th


SAN DIEGO, Nov. 28, 2011  /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) will host investors and analysts in New York City on December 5, 2011 for a corporate overview and update with a focus on its commercial strategy and launch of DIFICID.  A live webcast of the event will begin at 8:30 a.m. Eastern time and will be accessible on the Investors page of the Company's website at www.optimerpharma.com. A replay will be available for 90 days.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Speakers will include members of the executive management team as well as guest speaker Roy F. Chemaly, M.D., MPH, University of Texas MD Anderson Cancer Center.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and is commercializing DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer is seeking marketing authorization for fidaxomicin in the European Union and Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.


Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications

Canale Communications
Jason I. Spark, Senior Vice President


SOURCE Optimer Pharmaceuticals, Inc.

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.